Conference Reports for NATAP

62th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco 2011 Nov 6-9 Back

Daclatasvir (DCV; BMS-790052) Has No Clinically Significant Effect on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Female Subjects       Reported by Jules Levin AASLD Nov 5-8 2011 SF   Bifano M, Sevinsky H, Persson A, Hwang C, Kandoussi H, Jiang H, Grasela D, Bertz R Research & Development, Bristol-Myers Squibb, Hopewell, NJ   CONCLUSIONS   ·Co-administration of DCV and Ortho Tri-Cyclen® did not result in any clinically significant pharmacokinetic drug interactions, as assessed by ethinyl estradiol, norelgestromin, and norgestrel exposures   ·Contraceptive efficacy is likely to be maintained when a combined oral contraceptive containing ethinyl estradiol and norgestimate is co-administered with DCV   ·No significant pharmacokinetic drug interactions between other combined oral contraceptives and DCV are anticipated ·DCV was safe and generally well-tolerated in this study